TD Cowen Maintains Buy on Helus Pharma, Raises Price Target to $62
TD Cowen analyst Ritu Baral maintains Helus Pharma (NASDAQ:HELP) with a Buy and raises the price target from $8 to $62.
Stocks · News reference
Helus Pharma Completes Enrollment In Its APPROACH Phase 3 Study Of HLP003 In Patients Living With Major Depressive Disorder; Topline Data Readout On Track For Q4 2026
Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM ProgramParticipant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability dataHLP003 previously
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Helus Pharma Q1 EPS $(0.91) Beats $(1.07) Estimate
Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(1.07) by 14.95 percent. This is a 17.27 percent increase over losses of $(1.10) per share from the
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading include NAMI, BNED, YXT, TENX, MSC, B, VRSK, XFOR, HELP, and SLDB.
Helus Pharma Appoints Michael Halstead CEO, Effective Immediately
Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists